Connect with us

Hi, what are you looking for?


Nutura Organic Ltd – Term Sheet to commence Pilot Study

The Board of BPH Global Ltd (ASX: BP8) (Company) announces that the Company has entered into a legally binding Term Sheet (Term Sheet) with Australian-based company Nutura Organic Ltd (Nutura) for the purchase of adult milk formula to enable the Company to undertake a pilot study in China.


Purchase of adult milk formula to commence pilot study in ChinaProposed development of adult milk formula products infused with TCM ingredients including sialic acid and nutraceuticals extracted from raw birds’ nest and seaweedFocus on sales and distribution in China

Nutura is a Melbourne-based company which produces a range of nutrition products made exclusively from Australian sourced milk including its GB-compliant product ‘Adult 60+ Milk Formula’ (Adult Milk Formula). Nutura is interested in expanding its product and distribution footprint throughout China. “GB compliant” is a reference to a product which has passed the product testing protocols and procedures prescribed by the National Standards of the People’s Republic of China.

As part of it continuing focus on opportunities to purchase or produce food products which deliver Traditional Chinese Medicine (TCM)-based outcomes, the Company is keen to undertake a pilot program in China to test the market for the sale and distribution of Nutura’s Adult Milk Formula and the opportunities to infuse that formula with TCM-based ingredients including sialic acid and nutraceuticals extracted from raw birds’ nest and seaweed (Pilot Study).

By committing to purchase an initial quantity of the Adult Milk Formula, the Company can commence a pilot study in China to determine the feasibility and commerciality of selling the Adult Milk Formula infused with TCM-based ingredients in China, including:

The cost of shipping the Adult Milk Formula to China and clearing Chinese customs procedures and protocols;The cost of obtaining the TCM-based ingredients, either in Australia or China, and infusing those ingredients into the Adult Milk Formula;The cost of delivery of the Adult Milk Formula to retail outlets; andThe level of consumer demand.

Term Sheet

Key terms of the Term Sheet are as follows:

Product: Adult Milk Formula.Quantity and Price: 3,500 units at an aggregate purchase price of approximately AUD35,000, after a rebate provide by Nutura to support marketing and promotional activities associated with the Pilot Study (Purchase Order)Nutura to ensure that the Adult Milk Formula is GB compliant.The term of the Term Sheet is valid until completion of each of the Company’s and Nutura’s obligations regarding the Purchase OrderFuture Activities: Nutura and the Company will continue to discuss commercial opportunities for the supply of Nutura’s products in the Chinese markets for their mutual commercial benefit with a focus on the Adult Milk Formula infused with TCM-based ingredients and leveraging the Company’s sales and distribution network in China.

Click here for the full ASX Release

This post appeared first on

You May Also Like

Editor's Pick

For years the North Korean playbook was obvious to the world. The Democratic People’s Republic of Korea wanted to be the center of attention....

Editor's Pick

After the final lecture of my Fall 2022 International Economic Policy course (an undergraduate offering meant to introduce non-economics majors to the economics of...

Editor's Pick

In Risky Business: Why Insurance Markets Fail and What to Do About It (Yale University Press, 2023), economists Liran Einav (Stanford), Amy Finkelstein (MIT),...

Editor's Pick

Real gross domestic product rose at a revised 3.2 percent annualized rate in the third quarter versus a 0.6 percent rate of decline in...

Disclaimer:, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2024